| Date | Title | Description |
| 05.08.2022 | Akebia's anemia drug flunked Covid study — but count the bruised biotech 'extremely encouraged' | For as long as it’s existed — since 2007 and counting — Akebia has always billed itself as a kidney disease specialist. But as it grapples with a costly FDA rejection of its lead anemia drug, the biotech is doing whatever ... |
| 24.11.2021 | Akebia Therapeutics Announces Participation in Upcoming Investor Conferences | CAMBRIDGE, Mass., Nov. 24, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Exec... |
| 15.11.2021 | Akebia Therapeutics to Present at Jefferies London Healthcare Conference | CAMBRIDGE, Mass., Nov. 15, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Exec... |
| 05.11.2021 | Akebia Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Milestones | CAMBRIDGE, Mass. - Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, reported financial results for the third quarter ended September 30, 2021 an... |
| 04.11.2021 | Akebia Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Milestones - Form 8-K | Akebia Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Milestones
• Pre-commercialization activities underway in anticipation of March 29, 2022 PDUFA date
• Vadadustat marketing authorization applicat... |
| 29.10.2021 | Akebia Announces Otsuka's Submission of Initial Marketing Authorization Application to the European Medicines Agency for Vadadustat for the Treatment of Patients with Anemia due to Chronic Kidney Dise... | CAMBRIDGE, Mass., Oct. 29, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, and its collaborator, Otsuka Pharmaceutical ... |
| 01.09.2021 | Akebia Therapeutics : Announces September 2021 Investor Conference Schedule | CAMBRIDGE, Mass., Sept. 1, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Exec... |
| 01.09.2021 | Akebia Therapeutics Announces September 2021 Investor Conference Schedule | |
| 03.06.2021 | Akebia Therapeutics Announces Presentations at ERA-EDTA Virtual Congress 2021 | |
| 03.06.2021 | AKEBIA THERAPEUTICS, INC.
Akebia Therapeutics : Announces Presentations at ERA-EDTA Virtual Congress 2021 | CAMBRIDGE, Mass., June 3, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced presentations of data from the g... |
| 25.03.2021 | Akebia Therapeutics Announces Poster Presentations and Educational Symposium at National Kidney Foundation 2021 Virtual Spring Clinical Meetings | |
| 25.03.2021 | AKEBIA THERAPEUTICS, INC.
Akebia Therapeutics : Announces Poster Presentations and Educational Symposium at National Kidney Foundation 2021 Virtual Spring Clinical Meetings | CAMBRIDGE, Mass., March 25, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at t... |
| 24.03.2021 | Akebia Therapeutics Announces Approval for Additional Indication of Riona® (ferric citrate hydrate) for the Treatment of Iron Deficiency Anemia in Adult Patients in Japan | |
| 11.03.2021 | Akebia Therapeutics Celebrates World Kidney Day and National Kidney Month | |
| 11.03.2021 | Akebia Therapeutics Celebrates World Kidney Day and National Kidney Month | CAMBRIDGE, Mass., March 11, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, celebrates World Kidney Day and National Kidne... |
| 02.03.2021 | Akebia Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference | CAMBRIDGE, Mass., March 2, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Exec... |
| 02.03.2021 | Akebia Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference | |
| 25.02.2021 | Akebia Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Business Updates | |
| 06.01.2021 | Akebia Therapeutics to Present at H.C. Wainwright Bioconnect 2021 Conference | |
| 16.11.2020 | Akebia Announces Manuscript Highlighting Global Phase 3 INNO2VATE Program Rationale, Study Design and Baseline Characteristics Published in Peer-Reviewed Medical Journal | |
| 05.11.2020 | Akebia Reports Third Quarter 2020 Financial Results and Recent Business Updates | |
| 23.10.2020 | Akebia Presents Results from its PRO2TECT Global Phase 3 Program of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients Not on Dialysis During Late-Breaking Session ... | |
| 22.10.2020 | Akebia Presents Results from its INNO2VATE Global Phase 3 Program; Demonstrated Efficacy and Cardiovascular Safety of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Pati... | |
| 16.10.2020 | Seth Klarman Axes Akebia Therapeutics Stake From Portfolio | Baupost Group leader Seth Klarman (Trades, Portfolio) disclosed last week he divested of his position in Akebia Therapeutics Inc. (NASDAQ:AKBA). |
| 03.09.2020 | Akebia Therapeutics Announces Top-Line Results from its PRO2TECT Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients Not on Dialysis | |
| 28.09.2018 | Daily funding roundup - September 28th, 2018 | SoloLearn raised $5.6M; DAILYLOOK raised $8M; Broadly raised $10M; Covr raised $10M
SoloLearn: SoloLearnlets you learn and practice a skill of your choice anytime anywhere for free. It consists of very short videos and interactive checkpoin... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| 04.06.2013 | Akebia snags $41M financing in anemia-drug race with GlaxoSmithKline, others | In a race with rival programs from GlaxoSmithKline ($GSK) and Astellas Pharma, the biotech startup Akebia Therapeutics has rallied venture investors to fund its charge toward late-stage development of a novel anemia drug. Today the company ... |
| 04.06.2013 | Akebia Therapeutics Completes $41M Series C Financing | Akebia Therapeutics, a Cincinnati, OH-based biotech company focused on developing and commercializing small molecules to treat anemia and cancer, completed a $41m Series C financing.
The round was co-led by Satter Investment Management, LLC... |
| 04.06.2013 | Akebia Therapeutics Inks $41M Series C |
CINCINNATI, OH, Biotech company focused on developing and commercializing small molecules to treat anemia and cancer, today announced that it has completed a $41 million Series C financing.
>> Click here for more funding data on Ak... |
| 30.08.2012 | Vascular disease biopharma Aerpio nabs $27M for trials of diabetic macular edema drug | Aerpio will use the funds to proceed with a phase 1b/2a safety and efficacy study of AKB-9778 later this year and development of its inflammatory bowel disease drug. The funds should also carry the DME drug through a large phase 2 trial, th... |
| 09.01.2012 | Akebia Draws Down $4.1M Series B |
CINCINNATI, OH, Pharmaceutical discovery and development company focused on anemia has drawn down a $4.1M tranche of its previously announced Series B financing. Investors included Novartis Bioventures, Venture Investors LLC, Triathlon Me... |
| 09.01.2012 | Akebia Therapeutics Raises $4.1M in Series B Financing | Akebia Therapeutics, Inc., a Cincinnati, OH-based pharmaceutical discovery and development company focused on anemia, has drawn down a $4.1m tranche of its already announced Series B financing (read here).
Investors included Novartis Bioven... |
| 12.08.2011 | Beyond EPO injections: Anemia treatment that comes in a pill | The anemia market could be worth up to $10 billion annually. It’s dominated by injectable biologic drugs, such as Amgen’s Epogen and Aranesp and Johnson & Johnson’s Procrit, with Amgen holding most of the market. Those drugs generally w... |
| 27.04.2011 | Akebia Therapeutics Closes $22M Series B Financing | Akebia Therapeutics, Inc., a Cincinnati, OH-based pharmaceutical discovery and development company focused on anemia and vascular disorders, has closed a $22m Series B financing.
The round was led by existing investors Novartis Venture Fund... |
| 21.06.2010 | Akebia Therapeutics aims at needs of chronic anemia patients | Pharmaceutical companies have developed injectable drugs, called erythropoietin-stimulating agents (ESAs), to treat chronic anemia. But the drugs that boost erythropoietin — the hormone that stimulates the bone marrow to make more red blood... |
| 16.06.2010 | Akebia Therapeutics Raises $5M in Series A Financing Round | Akebia Therapeutics, Inc., a Cincinnati, OH-based pharmaceutical discovery and development company focused on anemia and vascular disorders, has completed the $5m second tranche of its $17m Series A financing round.
Investors in this tranch... |
| 03.03.2010 | Queen City Angels defy bad economy, invest in 8 health care companies | Akebia Therapeutics–Cincinnati biopharmaceutical company focused on the development of small molecules for the treatment of anemia and vascular disease.
AssureRx–The Mason, Ohio company that provides bioinformatics to select the right drug ... |
| 26.02.2010 | Cincinnati's Akebia starts Phase 1b clinical trial for anemia drug | During the Phase 1b trial, three doses of AKB-6548 will be administered to about 33 healthy volunteers at Cincinnati contract research organization Medpace Inc. over a 10-day period to evaluate the drug’s safety, tolerability and movement t... |
| 05.01.2010 | Akebia completes Phase I trial of anemia drug, looks toward licensing deal with large pharmaceutical firm | 2010 is shaping up to be a big year for Akebia. The company plans to begin Phase 1b and 2a clinical trials, and that’s only the beginning of what could turn into several major developments for the Cincinnati company this year. The primary... |
| 15.09.2009 | Cincinnati’s Akebia begins Phase I human study on anemia drug | The eight-member company has recently added two employees and will add two more. It could over the next year or so grow to about 20 depending in part on the clinical data it collects, Chief Executive Officer Joseph Gardner said.
The company... |
| 02.09.2009 | Akebia adds Dr. Victor Dzau, Duke Health CEO, to board of directors | Promoted
Covid-19’s terrible toll on diabetes patients. What can be done?
The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
| 29.07.2009 | Cardiovascular biopharma Akebia takes additional funding to develop 2 drugs | Promoted
Covid-19’s terrible toll on diabetes patients. What can be done?
The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
| 25.06.2009 | Cincinnati’s Akebia Therapeutics names new CFO | “We have a number of very exciting programs underway and Ian’s experience in capital management, corporate development and operations will be essential in helping the company successfully move into our next phase of value creation,†Dr.... |
| - | A top credit-risk firm says these are the 10 biotech companies most likely to go bankrupt | Credit Risk Monitor tracks the risk of bankruptcy across thousands of companies. Maksim Safaniuk/ Getty Images This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Insider got exclusive access... |
| - | Cincinnati’s Akebia Therapeutics names new CFO | CINCINNATI, Ohio — Anemia and vascular disorder drugmaker Akebia Therapeutics has named Ian A. W. Howes, the former chief financial officer at Serenex, its CFO and vice president of development (pdf).
Serenex was a lung-cancer drugmaker tha... |
| - | Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., March 2, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted five newly-hired employees options to p... |
| - | Is the HIF-PHI class of next-generation kidney drugs doomed in the U.S.? | The FDA’s recent complete response letter (CRL) for vadadustat — an oral therapy evaluated for the treatment of anemia in patients with chronic kidney disease (CKD) — was a big surprise and disappointment for our community. The trials had q... |
| - | Cincinnati’s Akebia begins Phase I human study on anemia drug | CINCINNATI, Ohio — Akebia Therapeutics on Tuesday said it started its first Phase I human study (pdf) of a pill meant to help create new red blood cells in anemia patients.
The drug, AKB-6548, is an alternative to injections of the erythrop... |
| - | Insider identified 13 drug companies that are in a dangerous financial position and struggling to survive through 2022 | Mark Foley, CEO of Revance Therapeutics, Cameron Durrant, CEO of Humanigen, Nick Leschly Former CEO of Bluebird Bio, and Henry Ji, CEO of Sorrento Therapeutics, Revance Therapeutics; Humanigen; Sorrento Therapeutics; Wendy Maeda/Getty Image... |
| - | Beyond EPO injections: Anemia treatment that comes in a pill | The pharmaceutical company Affymax just got $10 million for moving forward with an anemia treatment that would require one injection a month as opposed to as many as several shots a week.
Imagine the opportunity if someone can take a simila... |
| - | Cardiovascular biopharma Akebia takes additional funding to develop 2 drugs | CINCINNATI, Ohio — Cardiovascular drugmaker Akebia Therapeutics will add $10 million more than expected to its Series A fund-raise, bringing the total to $25 million, the company stated (pdf).
The company stated it raised additional money t... |
| - | Cincinnati's Akebia starts Phase 1b clinical trial for anemia drug | CINCINNATI, Ohio — Small molecule discovery and development company Akebia Therapeutics Inc. has started a second Phase 1 clinical trial of its anemia drug–another baton hand-off in a race with big drug companies to get to market first with... |
| - | Vascular disease biopharma Aerpio nabs $27M for trials of diabetic macular edema drug | A biopharmaceutical company that spun out of Cincinnati-based Akebia Therapeutics just eight months ago has raised $27 million to support development and clinical trials of its drug for diabetic macular edema.
Novartis BioVentures led Aerpi... |
| - | Akebia completes Phase I trial of anemia drug, looks toward licensing deal with large pharmaceutical firm | CINCINNATI, Ohio — Akebia Therapeutics has successfully completed a Phase I trial of its anemia drug in healthy human volunteers, the company announced.
The drug, a pill known as AKB-6548, was shown to successfully and safely produce the e... |
| - | Akebia Therapeutics aims at needs of chronic anemia patients | Being first isn’t the only goal in the drug-development business.
Sometimes, an unmet patient need is so great, companies that are second or third to market stand a good chance of success. That’s what Akebia Therapeutics Inc. near Cincinnat... |
| - | Queen City Angels defy bad economy, invest in 8 health care companies | Queen City Angels invested in seven life sciences companies and one health information technology company last year, according to its 2009 annual operating report (pdf).
The group of accredited investors finished the year with 12 investment... |
| - | Akebia Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Business Updates | CAMBRIDGE, Mass., Feb. 25, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, today reported financial results for the fou... |
| - | Akebia Therapeutics Announces Approval for Additional Indication of Riona® (ferric citrate hydrate) for the Treatment of Iron Deficiency Anemia in Adult Patients in Japan | CAMBRIDGE, Mass., March 24, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), today announced that its collaboration partner, Japan Tobacco Inc. (JT), received approval from the Pharmaceuticals and Medical Devices Agency (PMDA)... |
| - | Akebia adds Dr. Victor Dzau, Duke Health CEO, to board of directors | CINCNNATI, Ohio — Dr. Victor Dzau, the president and CEO of the Duke University Health System, has joined the board of directors of Akebia Therapeutics.
This adds heavyweight talent to some significant fund-raising by Akebia. Last month it ... |
